Timothy Springer Net Worth

The estimated Net Worth of Timothy A Springer is at least $159 Миллион dollars as of 3 May 2023. Mr. Springer owns over 1,050,000 units of Morphic Inc stock worth over $157,774,763 and over the last 8 years he sold MORF stock worth over $0. In addition, he makes $1,260,500 as Founder и Independent Director at Morphic Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Springer MORF stock SEC Form 4 insiders trading

Timothy has made over 23 trades of the Morphic Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,050,000 units of MORF stock worth $47,250,000 on 3 May 2023.

The largest trade he's ever made was buying 6,681,600 units of Morphic Inc stock on 11 April 2022 worth over $380,784,384. On average, Timothy trades about 665,691 units every 47 days since 2017. As of 3 May 2023 he still owns at least 2,768,464 units of Morphic Inc stock.

You can see the complete history of Mr. Springer stock trades at the bottom of the page.

Timothy Springer biography

Timothy A. Springer Ph.D. serves as Founder, Independent Director of the Company. Since 1989, Dr. Springer has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he is a founder and investor in Scholar Rock Holding Corporation and served as a member of its board from October 2012 to May 2019. He has also served Selecta Biosciences Inc. as a scientific advisor since December 2008 and as a member of its board since June 2016. Dr. Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer received a B.A. in Biochemistry from the University of California, Berkeley, and a Ph.D. in Biochemistry and Molecular Biology from Harvard University. Springer is qualified to serve on our board of directors because of his extensive knowledge of the integrin field and his investment, business and board experience with biopharmaceutical companies.

What is the salary of Timothy Springer?

As the Founder и Independent Director of Morphic Inc, the total compensation of Timothy Springer at Morphic Inc is $1,260,500. There are no executives at Morphic Inc getting paid more.

How old is Timothy Springer?

Timothy Springer is 71, he's been the Founder и Independent Director of Morphic Inc since 2015. There are 2 older and 17 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.

What's Timothy Springer's mailing address?

Timothy's mailing address filed with the SEC is 2nd Floor, 620 Memorial Dr, Cambridge, MA 02139, United States.

Insiders trading at Morphic Inc

Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo и Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.

What does Morphic Inc do?

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Complete history of Mr. Springer stock trades at Selecta Biosciences Inc, Scholar Rock Corp и Morphic Inc

Morphic Inc executives and stock owners

Morphic Inc executives and other stock owners filed with the SEC include:

• Timothy Springer,
  Founder, Independent Director
• Alexey Lugovskoy,
  Chief Development Officer
• Dr. Praveen P. Tipirneni M.D.,
  CEO, Pres & Director
• William DeVaul,
  General Counsel, Secretary
• Praveen Tipirneni,
  President, Chief Executive Officer, Director
• Dr. Marc Schegerin M.B.A., M.D.,
  CFO & COO
• Bruce Rogers,
  Chief Scientific Officer
• Vikas Goyal,
  Independent Director
• Gustav Christensen,
  Independent Chairman of the Board
• Joseph Slattery,
  Independent Director
• Otello Stampacchia,
  Independent Director
• Norbert Bischofberger,
  Independent Director
• Amir Nashat,
  Independent Director
• Dr. Timothy A. Springer Ph.D.,
  Founder, Independent Director & Member of Scientific Advisory Board
• Nilesh Kumar,
  Independent Director
• Peter Linde,
  Chief Medical Officer
• Robert Farrell,
  Senior Vice President - Finance, Chief Accounting Officer
• Marc Schegerin,
  Chief Financial Officer, Chief Operating Officer
• Adrian S. Ray Ph.D.,
  Sr. VP and Head of Biology & Translation
• Blaise Lippa,
  Sr. VP of Molecular Discovery
• William D. DeVaul Esq.,
  Gen. Counsel & Sec.
• Dr. Bruce N. Rogers,
  Chief Scientific Officer
• Robert E. Farrell Jr., CPA, CPA,
  Sr. VP of Fin./Operations & Chief Accounting Officer
• Susannah Gray,
  
• Nisha Nanda,
  
• Martin Edwards,
  
• Holdings A/S Novo,
  10% owner
• Plc Gsk,
  Director
• Otello Stampacchia,
  Director
• Fund V, L.P.Omega Fund V Gp...,
  
• Simon Peter Cooper,
  CMO